-+ 0.00%
-+ 0.00%
-+ 0.00%

Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema

Barchart·10/02/2026 07:00:00
Listen to the news

First patient expected to be dosed in the DUET study in the fourth quarter of 2026

Milestone triggers second closing of March 2025 private placement expected to provide approximately $95.1M in gross proceeds

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.